Nij Terahertz-ynstrumint Bringt Molekulêre Hânichheid yn Kaart, Mar Wa Wint Derfan?
June 2, 2026 · Frisian News
Researchers developed a terahertz imaging technique that maps chiral structures in materials at 100-micrometer resolution. The breakthrough raises questions about pharmaceutical development, who funds this research, and whether drug makers will actually use it.
FryskIn team fan natuerkundigen kundige oan dat hja no chirale molekulen, dy draaide struktueren dy't as spegelbyld fan inoar besteane mar net oerlape kinne, mei bûtengewoane helderheid ôfbylde kinne. De terahertz-ôfbyldingstechnyk berikket 100-mikrometer resolúsje en bringt yn kaart wêr't loftshannige en rjochtshannige ferzjes yn in materiaal sitte. Dit is fan belang om't in protte medisinen allinne yn ien chirale foarm wurkje, wylst it spegelbyld ynert of skealik wêze kin. De trochbraak klinkt as suver wittenskiplike foarútgong, mar it praktyske ferhaal is minder oersichtlik.
Chiraliteit is al tsientallen jierren in bekend probleem yn de farmasyske fabrikaazje. Bedriuwen skieie chirale molekulen al mei help fan besteande metoaden, súlenchromatografy is de standert yn yndustriële omjouwings. Hja kontrôlearje medisinen op suverheid en identifisearje net winske spegelfoarmen foardat se op 'e merk geane. De fraach is net oft de yndustry dizze technology nedich hat, mar oft hja dizze op grutte skaal echt brûke sil. Akademyske labs hâlde fan nije ôfbyldingsark. Fabryksflierren hâlde fan wat hja al kenne en minder kostet om út te fieren.
Wa finansiert dit ûndersyk? It persberjocht seit it noait. Oerheidssúbsydzjes, universiteitsbudzjetten, gearwurkingsferbânen mei farmasyske bedriuwen, of in miks fan alles. As in technyk út in universitêr lab komt en yn in tydskrift publisearre wurdt, sit it finansiersferhaal meastentiids yn lytse letters oan 'e ein. Dochs feroaret dy kontekst alles. In farmabedriuw dat dit wurk finansiert, hopet it miskien foar konkurrinsjefoardiel yn te setten. In regearing wol miskien bettere kwaliteitskontrôle op ynfierde medisinen. In universiteit wol miskien krantekoppen foar subsydzjeoanfragen. Gjin fan dizze finansiers binne neutrale waarnimmers.
De echte test komt dan. Set de farmasyske yndustry, al wis fan hjoeddeistige metoaden, jild út om produksjeregels mei terahertz-ôfbyldingsapparatuer om te bouwen? Of bliuwe universiteiten artikelen oer terahertz-ôfbylding publisearje wylst fabryken chromatografy-súlen bliuwe draaien? De skiednis suggerearret it twadde. De measte publisearre wittenskiplike trochbraken berikke produksje net, om't hja problemen oplosse dy't fabryken lang lyn op oare manieren oplost hawwe. De kosten fan feroaring, omskeling fan personiel en validaasjetests wegen faak op tsjin it foardiel.
Wat no fan belang is, is net de technyske prestaasje mar it adopsje-ferhaal dat him oer fiif jier ûntwikkelet. As gjin grutte medisinfabrikant dizze technology ynset, wurdt it resultaat wat it altyd yn akademyske wittenskip west hat: in tûk ark dat briljant yn it lab wurket en stof ferzamelet yn 'e echte wrâld. It ûndersyk sels is degelik. It winstpotinsjeel is minder dúdlik as de keppelins suggerearje.
A team of physicists announced they can now image chiral molecules, those twisted structures that exist as mirror images of each other but cannot overlap, with unprecedented clarity. The terahertz imaging technique reaches 100-micrometer resolution and maps where left-handed and right-handed versions sit in a material. This matters because many drugs work only in one chiral form, while the mirror image can be inert or harmful. The breakthrough sounds like pure science progress, but the practical story is messier.
Chirality has been a known problem in pharmaceutical manufacturing for decades. Companies already separate chiral molecules using established methods, column chromatography being the standard industrial workhorse. They screen drugs for purity and identify unwanted mirror forms before market approval. The question is not whether industry needs this technology, but whether it will actually adopt it at scale. Academic labs love novel imaging tools. Factory floors love what they already know works and costs less to run.
Who funds this research? The press release never says. Government grants, university budgets, pharmaceutical company partnerships, or some mix of all three. When a technique comes from a university lab and gets published in a journal, the funding story usually sits in fine print at the end. Yet that context changes everything. A pharma company funding this work might hope to use it for competitive advantage. A government might want better quality control on imported medications. A university might want headlines for grant proposals. None of these funders are neutral observers.
The real test comes next. Does the pharmaceutical industry, already confident in current methods, spend money retrofitting production lines with terahertz imaging gear? Or do universities keep publishing papers about terahertz imaging while factories continue running chromatography columns? History suggests the latter. Most published scientific breakthroughs do not reach production because they solve problems factories solved long ago in different ways. The cost of switching, staff retraining, and validation tests often outweighs the benefit.
What matters now is not the technical achievement but the adoption story that unfolds over five years. If no major drug manufacturer deploys this technology, the result becomes what it always has been in academic science: a clever tool that works brilliantly in the lab and gathers dust in the real world. The research itself is sound. The profit potential is less clear than the headlines suggest.
Published June 2, 2026 · Frisian News · Ljouwert, Fryslân